E2F-1在肝细胞癌中的表达情况及其对患者预后的影响研究

摘要

Objective To investigate the expression of E2F-1 in hepatocellular carcinoma and its effect on prognosis. Methods The pathological specimens from 79 cases of patients with liver cancer underwent radical resection in our hospital from January 2006 to December 2011 were collected. 30 cases of para-carcinoma tissues that were more than 5 cm away from neoplastic foci were compared. The expression of E2F-1 was detected by immunohistochemistry. The expression difference of tumor tissue and para-carcinoma tissue was compared to analyze the expression of E2F-1, the correlation between clinicopathological parameters and its effect on postoperative survival time. Results Among 79 cases of patients with tumor tissues,E2F-1 positive expression could be found among 39 cases with the positive rate of 49.4%;E2F-1 expression could not be found among 30 cases of patients with para-carcinoma tissue. The positive expression rates of E2F-1 in tumor tissues and adjacent tissues were significantly different(P<0.05). The expression of E2F-1 was related to AFP level,TNM staging and tumor diameter decrease. With the decrease of AFP level,TNM staging and tumor diameter,the expression of E2F-1 was higher(P<0.05)but it was not related to age,HBsAg infection,GGT and tumor number(P>0.05). The total survival rates of E2F-1 positive group were 61.5%,59%,46.2% respectively in one,three and five years. The total survival rates of E2F-1 negative group were 37.5%、32.5%、17.5% respectively in one,three and five years. For the comparison among groups,the total survival rates of E2F-1 positive group were all higher than those of the E2F-1 negative group(P<0.05)in one,three and five years. Conclusions E2F-1 shows high expression in hepatocellular carcinoma tissues,the expression level is related to AFP level,tumor diameter and clinical staging.The E2F-e low expression is an independent prognostic factor of overall survival rate after liver cancer operation so that it can be used as an independent prognostic factor after liver cancer resection.%目的 分析E2F-1在肝细胞癌中的表达,探讨E2F-1对患者预后的影响.方法 收集2006年1月至2011年12月行根治性切除术的79例肝癌患者的病理标本为研究对象.取距离癌灶>5cm的癌旁组织30例作为对照.采用免疫组化法检测E2F-1的表达情况.对比肿瘤组织与癌旁组织E2F-1的表达差异,分析E2F-1的表达与临床病理参数间的相关性及对术后生存时间的影响.结果 79例肿瘤组织中E2F-1阳性表达39例,阳性率为49.4%;30例癌旁组织中未见E2F-1表达.肿瘤组织与癌旁组织中的E2F-1阳性表达率具显著性差异(P<0.05).E2F-1的表达与AFP水平、TNM分期及肿瘤直径相关,随着AFP水平的下降,TNM分期的降低及肿瘤直径的减小,E2F-1的表达越高(P<0.05);而与患者的年龄、HBsAg感染情况、GGT及肿瘤数量等无关(P>0.05).E2F-1阳性组总体1、3、5年生存率分别为61.5%、59.0%、46.2%,阴性组总体1、3、5年生存率分别为37.5%、32.5%、17.5%,组间比较E2F-1阳性组总体1、3、5年生存率均高于E2F-1阴性组(P<0.05).结论 E2F-1在肝癌组织中呈高表达,其表达水平与AFP水平、肿瘤直径及临床分期相关;E2F-1低表达是肝癌术后的总体生存率的独立预后因素,可作为肝癌根治切除术后的独立预后因子.